The Alzheimer's amyloid β-peptide (Aβ) binds a specific DNA Aβ-interacting domain (AβID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: Characterizing a new regulatory motif

Gene

Volumn 488, Issue 1-2, 2011, Pages 1-12

  Maloney, Bryan ^a   Lahiri, Debomoy K ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; DNA protein interaction; Gene regulation; Transcription factor

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE 1; DNA; LYSYLGLYCYLGLYCYLARGINYLLYSYLTHREONYLGLYCYLGLYCYLGLYCYLGLYCYINE; PEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CYTOTOXICITY; DNA FLANKING REGION; GEL MOBILITY SHIFT ASSAY; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; APOLIPOPROTEINS E; ASPARTIC ACID ENDOPEPTIDASES; BASE SEQUENCE; CONSENSUS SEQUENCE; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; PEPTIDE FRAGMENTS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; TRANSCRIPTION FACTORS;

EID: 80053385335     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2011.06.004     Document Type: Article

References (89)

1. Bailey J.A., Lahiri D.K. A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J. Neurochem. 2010, 112:843-853.
2. Bailey J.A., Maloney B., Ge Y.-W., Lahiri D.K. Functional activity of the novel Alzheimer's amyloid β-peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. Gene 2011, 488:13-22.
3. Barrantes A., Rejas M.T., Benitez M.J., Jimenez J.S. Interaction between Alzheimer's Abeta1-42 peptide and DNA detected by surface plasmon resonance. J. Alzheimers Dis. 2007, 12:345-355.
4. Baruch-Suchodolsky R., Fischer B. Abeta40, either soluble or aggregated, is a remarkably potent antioxidant in cell-free oxidative systems. Biochemistry 2009, 48:4354-4370.
5. Bogoyevitch M.A., Boehm I., Oakley A., Ketterman A.J., Barr R.K. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim. Biophys. Acta 2004, 1697:89-101.
6. Checler F., Dunys J., Pardossi-Piquard R., Alves da Costa C. p53 is regulated by and regulates members of the gamma-secretase complex. Neurodegener. Dis. 2010, 7:50-55.
7. Chin J.H., Ma L., MacTavish D., Jhamandas J.H. Amyloid beta protein modulates glutamate-mediated neurotransmission in the rat basal forebrain: involvement of presynaptic neuronal nicotinic acetylcholine and metabotropic glutamate receptors. J. Neurosci. 2007, 27:9262-9269.
8. Christensen M.A., Zhou W., Qing H., Lehman A., Philipsen S., Song W. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol. Cell Biol. 2004, 24:865-874.
9. Crescenzi O., Tomaselli S., Guerrini R., Salvadori S., D'Ursi A.M., Temussi P.A., Picone D. Solution structure of the Alzheimer amyloid beta-peptide (1-42) in an apolar microenvironment. Similarity with a virus fusion domain. Eur. J. Biochem. 2002, 269:5642-5648.
10. Cuesta A., Zambrano A., Royo M., Pascual A. The tumour suppressor p53 regulates the expression of amyloid precursor protein (APP). Biochem. J. 2009, 418:643-650.
11. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol. Rev. 2010, 90:465-494.
12. Dosunmu R., Wu J., Adwan L., Maloney B., Basha M.R., McPherson C.A., Harry G.J., Rice D.C., Zawia N.H., Lahiri D.K. Lifespan profiles of Alzheimer's disease-associated genes and products in monkeys and mice. J. Alzheimers Dis. 2009, 18:211-230.
13. Du Y., Chen X., Wei X., Ge Y.-W., Bales K.R., Berg D.T., Paul S.M., Farlow M.R., Lahiri D.K. NF-kappaB mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells. Brain Res. Mol. Brain Res. 2005, 136:177-188.
14. Durell S.R., Guy H.R., Arispe N., Rojas E., Pollard H.B. Theoretical models of the ion channel structure of amyloid beta-protein. Biophys. J. 1994, 67:2137-2145.
15. Eckman E.A., Eckman C.B. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 2005, 33:1101-1105.
16. Farris W., Mansourian S., Leissring M.A., Eckman E.A., Bertram L., Eckman C.B., Tanzi R.E., Selkoe D. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4162-4167.
17. Ge Y.-W., Ghosh M., Song W., Maloney B., Lahiri D. Mechanism of promoter activity of the beta-amyloid precursor protein gene in different cell types. Identification of a specific 30 bp fragment in the proximal promoter region. J. Neurochem. 2004, 90:1432-1444.
18. Giliberto L., et al. Mutant presenilin 1 increases the expression and activity of BACE1. J. Biol. Chem. 2009, 284:9027-9038.
19. Girish V., Vijayalakshmi A. Affordable image analysis using NIH Image/ImageJ. Indian J. Cancer 2004, 41:47.
20. Gouras G.K., Tsai J., Naslund J., Vincent B., Edgar M., Checler F., Greenfield J.P., Haroutunian V., Buxbaum J.D., Xu H., Greengard P., Relkin N.R. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000, 156:15-20.
21. Grilli M., Ribola M., Alberici A., Valerio A., Memo M., Spano P. Identification and characterization of a kappa B/Rel binding site in the regulatory region of the amyloid precursor protein gene. J. Biol. Chem. 1995, 270:26774-26777.
22. Guyant-Marechal L., Rovelet-Lecrux A., Goumidi L., Cousin E., Hannequin D., Raux G., Penet C., Ricard S., Mace S., Amouyel P., Deleuze J.F., Frebourg T., Brice A., Lambert J.C., Campion D. Variations in the APP gene promoter region and risk of Alzheimer disease. Neurology 2007, 68:684-687.
23. Hattori M., Tsukahara F., Furuhata Y., Tanahashi H., Hirose M., Saito M., Tsukuni S., Sakaki Y. A novel method for making nested deletions and its application for sequencing of a 300 kb region of human APP locus. Nucleic Acids Res 1997, 25:1802-1808.
24. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60:1119-1122.
25. Hussain I., et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol. Cell. Neurosci. 1999, 14:419-427.
26. Igbavboa U., Sun G.Y., Weisman G.A., He Y., Wood W.G. Amyloid beta-protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytes. Neuroscience 2009, 162:328-338.
27. Iqbal K., Liu F., Gong C.X., Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 2010, 7:656-664.
28. Jang H., et al. Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6538-6543.
29. Kimberly W.T., Zheng J.B., Guenette S.Y., Selkoe D.J. The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J. Biol. Chem. 2001, 276:40288-40292.
30. Konietzko U., Goodger Z., Meyer M., Kohli B., Bosset J., Lahiri D.K., Nitsch R.M. Co-localization of the amyloid precursor protein and Notch intracellular domains in nuclear transcription factories. Neurobiol. Aging 2010, 31:58-73.
31. Kovacs D.M., Wasco W., Witherby J., Felsenstein K.M., Brunel F., Roeder R.G., Tanzi R.E. The upstream stimulatory factor functionally interacts with the Alzheimer amyloid beta-protein precursor gene. Human Molecular Genetics 1995, 4:1527-1533.
32. La Fauci G., Lahiri D.K., Salton S.R., Robakis N.K. Characterization of the 5′-end region and the first two exons of the beta-protein precursor gene. Biochem. Biophys. Res. Commun. 1989, 159:297-304.
33. Lahiri D.K., Maloney B. Beyond the signaling effect role of amyloid-beta(42) on the processing of APP, and its clinical implications. Exp. Neurol. 2010, 225:51-54.
34. Lahiri D.K., Maloney B. The "LEARn" (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps. Exp. Gerontol. 2010, 45:291-296.
35. Lahiri D.K., Robakis N.K. The promoter activity of the gene encoding Alzheimer beta-amyloid precursor protein (APP) is regulated by two blocks of upstream sequences. Brain Res. Mol. Brain Res. 1991, 9:253-257.
36. Lahiri D.K., Nall C., Ge Y.W. Promoter activity of the beta-amyloid precursor protein gene is negatively modulated by an upstream regulatory element. Brain Res. Mol. Brain Res. 1999, 71:32-41.
37. Lahiri D.K., Song W., Ge Y.W. Analysis of the 5'-flanking region of the beta-amyloid precursor protein gene that contributes to increased promoter activity in differentiated neuronal cells. Brain Res. Mol. Brain Res. 2000, 77:185-198.
38. Lahiri D.K., Farlow M.R., Greig N.H., Sambamurti K. Current drug targets for Alzheimer's disease treatment. Drug Dev. Res. 2002, 56:267-281.
39. Lahiri D.K., Farlow M.R., Sambamurti K., Greig N.H., Giacobini E., Schneider L.S. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr. Drug Targets 2003, 4:97-112.
40. Lahiri D.K., Wavrant De-Vrieze F., Ge Y.-W., Maloney B., Hardy J. Characterization of two APP gene promoter polymorphisms that appear to influence risk of late-onset Alzheimer's disease. Neurobiol. Aging 2005, 26:1329-1341.
41. Lahiri D.K., Maloney B., Bailey J., Ge Y.-W. Role of alzheimer's amyloid-beta peptide as a putative transcription factor. Peptides: Breaking Away, Proceedings of the Twenty-First American Peptide Symposium 2009, 185-186. Prompt Scientific Publishing, Bloomington, Indiana, USA. M. Lebl (Ed.).
42. Lahiri D.K., Maloney B., Zawia N.H. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol. Psychiatry 2009, 14:992-1003.
43. Leissring M.A., et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003, 40:1087-1093.
44. Lu T., et al. Gene regulation and DNA damage in the ageing human brain. Nature 2004, 429:883-891.
45. Lukiw W.J., Rogaev E.I., Wong L., Vaula G., McLachlan D.R., St George Hyslop P. Protein-DNA interactions in the promoter region of the amyloid precursor protein (APP) gene in human neocortex. Brain Res. Mol. Brain Res. 1994, 22:121-131.
46. Lv H., Jia L., Jia J. Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer's disease. Neurobiol. Aging 2008, 29:194-202.
47. Maloney B., Ge Y.W., Greig N.H., Lahiri D.K. Characterization of the human beta-secretase 2 (BACE2) 5β-Flanking region: identification of a 268-bp region as the basal BACE2 promoter. J. Mol. Neurosci. 2006, 29:81-99.
48. Maloney B., Ge Y.W., Petersen R.C., Hardy J., Rogers J.T., Perez-Tur J., Lahiri D.K. Functional characterization of three single-nucleotide polymorphisms present in the human APOE promoter sequence: Differential effects in neuronal cells and on DNA-protein interactions. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:185-201.
49. Millucci L., Ghezzi L., Bernardini G., Santucci A. Conformations and biological activities of amyloid beta peptide 25-35. Curr. Protein Pept. Sci. 2010, 11:54-67.
50. Morgan C., Colombres M., Nunez M.T., Inestrosa N.C. Structure and function of amyloid in Alzheimer's disease. Prog. Neurobiol. 2004, 74:323-349.
51. Ohyagi Y., Tabira T. Intracellular amyloid beta-protein and its associated molecules in the pathogenesis of Alzheimer's disease. Mini. Rev. Med. Chem. 2006, 6:1075-1080.
52. Ohyagi Y., et al. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J. 2005, 19:255-257.
53. Ohyagi Y., et al. Intraneuronal amyloid beta42 enhanced by heating but counteracted by formic acid. J. Neurosci. Methods 2007, 159:134-138.
54. Ono K., Condron M.M., Teplow D.B. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14745-14750.
55. Paik Y.K., Chang D.J., Reardon C.A., Davies G.E., Mahley R.W., Taylor J.M. Nucleotide sequence and structure of the human apolipoprotein E gene. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:3445-3449.
56. Postel E.H., Berberich S.J., Flint S.J., Ferrone C.A. Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis. Science 1993, 261:478-480.
57. Sambamurti K., Kinsey R., Maloney B., Ge Y.W., Lahiri D.K. Gene structure and organization of the human beta-secretase (BACE) promoter. FASEB J. 2004, 18:1034-1036.
58. Sambamurti K., Greig N.H., Utsuki T., Barnwell E.L., Sharma E., Mazell C., Bhat N.R., Kindy M.S., Lahiri D.K., Pappolla M.A. Targets for AD treatment: conflicting messages from gamma-secretase inhibitors. J. Neurochem. 2011, 117:359-374.
59. Sayers E.W., et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2011, 39:D38-D51.
60. Schmid C.D., Perier R., Praz V., Bucher P. EPD in its twentieth year: towards complete promoter coverage of selected model organisms. Nucleic Acids Res. 2006, 34:D82-D85.
61. Schneider T.D. Consensus sequence Zen. Appl. Bioinformatics 2002, 1:111-119.
62. Schneider T.D., Stephens R.M. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 1990, 18:6097-6100.
63. Selkoe D.J., Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 2003, 43:545-584.
64. Shannon C.E. The mathematical theory of communication. 1963. MD Comput. 1997, 14:306-317.
65. Shao H., Jao S., Ma K., Zagorski M.G. Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease. J. Mol. Biol. 1999, 285:755-773.
66. Sheng J.G., Mrak R.E., Griffin W.S. Apolipoprotein E distribution among different plaque types in Alzheimer's disease: implications for its role in plaque progression. Neuropathol. Appl. Neurobiol. 1996, 22:334-341.
67. Shie F.S., LeBoeuf R.C., Jin L.W. Early intraneuronal Abeta deposition in the hippocampus of APP transgenic mice. NeuroReport 2003, 14:123-129.
68. Sinha S., et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999, 402:537-540.
69. Sosinsky A., Bonin C.P., Mann R.S., Honig B. Target Explorer: an automated tool for the identification of new target genes for a specified set of transcription factors. Nucleic Acids Res. 2003, 31:3589-3592.
70. Sun X., Wang Y., Qing H., Christensen M.A., Liu Y., Zhou W., Tong Y., Xiao C., Huang Y., Zhang S., Liu X., Song W. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. Faseb. J. 2005, 19:739-749.
71. Syrjanen S., Heinonen O., Miettinen R., Paljarvi L., Syrjanen K., Riekkinen P. Short biotinylated oligonucleotides bind non-specifically to senile plaques of Alzheimer's disease. Neurosci. Lett. 1991, 130:89-91.
72. Tabaton M., Zhu X., Perry G., Smith M.A., Giliberto L. Signaling effect of amyloid-beta(42) on the processing of AbetaPP. Exp. Neurol. 2010, 221:18-25.
73. Tamagno E., et al. JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1. Neurobiol. Aging 2009, 30:1563-1573.
74. Thies W., Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 2011, 7:208-244.
75. Tomaselli S., et al. The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. ChemBioChem 2006, 7:257-267.
76. Uchida Y., Nakano S., Gomi F., Takahashi H. Differential regulation of basic helix-loop-helix factors Mash1 and Olig2 by beta-amyloid accelerates both differentiation and death of cultured neural stem/progenitor cells. J. Biol. Chem. 2007, 282:19700-19709.
77. Vassar R., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
78. von Hippel P.H. Protein-DNA recognition: new perspectives and underlying themes. Science 1994, 263:769-770.
79. von Rotz R.C., et al. The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J. Cell Sci. 2004, 117:4435-4448.
80. Walsh D.M., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
81. Wang S., Jia J. Promoter polymorphisms which modulate BACE1 expression are associated with sporadic Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:159-166.
82. Wang Y.P., et al. Endogenous overproduction of beta-amyloid induces tau hyperphosphorylation and decreases the solubility of tau in N2a cells. J. Neural Transm. 2006, 113:1723-1732.
83. Wang Z.F., et al. Effects of endogenous beta-amyloid overproduction on tau phosphorylation in cell culture. J. Neurochem. 2006, 98:1167-1175.
84. Yan R., et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999, 402:533-537.
85. Yao Z.X., Papadopoulos V. Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. FASEB J. 2002, 16:1677-1679.
86. Yokota O., et al. Variability and heterogeneity in Alzheimer's disease with cotton wool plaques: a clinicopathological study of four autopsy cases. Acta Neuropathol. 2003, 106:348-356.
87. Zawia N.H., Sharan R., Brydie M., Oyama T., Crumpton T. Sp1 as a target site for metal-induced perturbations of transcriptional regulation of developmental brain gene expression. Brain Res Dev Brain Res 1998, 107:291-298.
88. Zhang X., et al. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J. Biol. Chem. 2007, 282:10873-10880.
89. Zou K., Gong J.S., Yanagisawa K., Michikawa M. A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J. Neurosci. 2002, 22:4833-4841.